Anticoagulation in patients at high risk of stroke without documented atrial fibrillation. Time for a paradigm shift?

被引:17
|
作者
Bayes de Luna, Antoni [1 ]
Baranchuk, Adrian [2 ]
Martinez-Selles, Manuel [3 ]
Platonov, Pyotr G. [4 ,5 ]
机构
[1] St Pau Hosp, Catalan Inst Cardiovasc Sci, Barcelona, Spain
[2] Queens Univ, Kingston Gen Hosp, Heart Rhythm Serv, Kingston, ON, Canada
[3] Univ Complutense, Univ Europea, Hosp Univ Gregorio Maranon, Cardiol Dept, Madrid, Spain
[4] Lund Univ CIEL, Ctr Integrat Electrocardiol, Lund, Sweden
[5] Skane Univ Hosp, Arrhythmia Clin Sweden, Lund, Sweden
关键词
ADVANCED INTERATRIAL BLOCK; HIGH CHADS(2) SCORE; MADIT II PATIENTS; P-WAVE DURATION; ISCHEMIC-STROKE; RETROGRADE ACTIVATION; CRYPTOGENIC STROKE; CATHETER ABLATION; CARDIOMYOPATHY; POPULATION;
D O I
10.1111/anec.12417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is currently considered a risk factor for stroke. Depending on the severity of clinical factors (risk scores) a recommendation for full anticoagulation is made. Although AF is most certainly a risk factor for ischemic stroke, it is not necessarily the direct cause of it. The causality of association between AF and ischemic stroke is questioned by the reported lack of temporal relation between stroke events and AF paroxysms (or atrial high-rate episodes detected by devices). In different studies, only 2% of patients had subclinical AF > 6 minutes in duration at the time of stroke or systemic embolism. Is it time to consider AF only one more factor of endothelial disarray rather than the main contributor to stroke? In this "opinion paper" we propose to consider not only clinical variables predicting AF/stroke but also electrocardio-graphic markers of atrial fibrosis, as we postulate this as a strong indicator of risk of AF/stroke. We ask if it is time to change the paradigm and to consider, in some special situations, to protect patients (preventing stroke) who have no evidence of AF.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Improving risk stratification in atrial fibrillation: Renal dysfunction and risk of thromboembolism and death in nonvalvular atrial fibrillation. The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
    Go, AS
    Hylek, EM
    Udaltsova, N
    Chang, YC
    Jensvold, NG
    Henault, LE
    Singer, DE
    CIRCULATION, 2004, 109 (07) : E92 - E92
  • [42] Residual risk of thromboembolic events despite anticoagulation in Middle Eastern patients with atrial fibrillation. The JoFib study
    Al-Nusair, Mohammed
    Alrabadi, Nasr
    Haddad, Razan
    Njem, Sumaya
    Aljarrah, Mohammad I.
    Hammoudeh, Ayman
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2024, 33 (08):
  • [43] ARE PATIENTS WITH STROKE AND ATRIAL FIBRILLATION RECEIVING APPROPRIATE ANTICOAGULATION?
    Phyu, Cho Thae
    Taylor, Caroline
    Khan, Zainab
    Cowell, Richard
    HEART, 2014, 100 : A7 - A7
  • [44] Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation
    Meinel, Thomas R.
    Branca, Mattia
    De Marchis, Gian Marco
    Nedeltchev, Krassen
    Kahles, Timo
    Bonati, Leo
    Arnold, Marcel
    Heldner, Mirjam R.
    Jung, Simon
    Carrera, Emmanuel
    Dirren, Elisabeth
    Michel, Patrik
    Strambo, Davide
    Cereda, Carlo W.
    Bianco, Giovanni
    Kagi, Georg
    Vehoff, Jochen
    Katan, Mira
    Bolognese, Manuel
    Backhaus, Roland
    Salmen, Stephan
    Albert, Sylvan
    Medlin, Friedrich
    Berger, Christian
    Schelosky, Ludwig
    Renaud, Susanne
    Niederhauser, Julien
    Bonvin, Christophe
    Schaerer, Michael
    Mono, Marie-Luise
    Rodic, Biljana
    Tarnutzer, Alexander A.
    Mordasini, Pasquale
    Gralla, Jan
    Kaesmacher, Johannes
    Engelter, Stefan
    Fischer, Urs
    Seiffge, David J.
    ANNALS OF NEUROLOGY, 2021, 89 (01) : 42 - 53
  • [45] Antithrombotic Bridging in Patients With Acute Ischemic Stroke and Atrial Fibrillation.
    Swafford, Kara
    Lee, Jessica D.
    STROKE, 2019, 50
  • [46] Patients with Thyroid Cancer on TSH Suppression Have a High Risk of Atrial Fibrillation.
    Abonawara, A.
    Quraishi, A.
    Sapp, J.
    Al-Qamber, M.
    O'Connell, C. M.
    Hart, R.
    Rajaraman, M.
    Imran, S. A.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [47] Reduced stroke risk without increased bleeding risk in patients with atrial fibrillation and complicated liver cirrhosis treated with oral anticoagulation
    Steensig, K.
    Pareek, M.
    Krarup, A. L.
    Sogaard, P.
    Maeng, M.
    Tayal, B.
    Torp-Pedersen, C.
    Lip, G. Y. H.
    Holland-Fischer, P.
    Kragholm, K. H.
    EUROPEAN HEART JOURNAL, 2020, 41 : 658 - 658
  • [48] Factors Correlated with Anticoagulation Choice in Primary Care Patients with Atrial Fibrillation and High Stroke Risk: Anticoagulation for NVAF in Primary Care
    Weng, Chien-Hsiang
    Kuo, Hsu-Ko
    Aho, Benjamin
    McGookin, Edward D.
    Chan, Philip A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, 39 (16) : 3234 - 3242
  • [49] Identifying Patients at High Risk for Stroke Despite Anticoagulation A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort
    Lip, Gregory Y. H.
    Frison, Lars
    Halperin, Jonathan L.
    Lane, Deirdre A.
    STROKE, 2010, 41 (12) : 2731 - 2738
  • [50] Oral anticoagulation in atrial fibrillation Balancing the risk of stroke with the risk of bleed
    Kosar, Lynette
    Jin, Margaret
    Kamrul, Rejina
    Schuster, Brenda
    CANADIAN FAMILY PHYSICIAN, 2012, 58 (08) : 850 - 858